EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement

Jana Nabki iD, Bashar Al Deeban iD, Abel Mehari Sium, Chiara Cosentino iD, Mohammad Almasri iD, Bassel Awikeh, Nawar Maher, Matteo Bellia, Riccardo Dondolin, Samir Mouhssine iD, Donatella Talotta, Eleonora Secomandi und 18 weitere

Leukemia · 2025

DOI: 10.1038/s41375-024-02499-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, 2025. Verfasst von Jana Nabki und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Immunoglobulin Light Chains, Mutation, Immunoglobulin Variable Region. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mutational status of immunoglobulin (IG) light chain genes in chronic lymphocytic leukemia (CLL) and its clinical impact have not been extensively studied. To assess their prognostic significance, the IG light chain gene repertoire in CLL patients has been evaluated using a training-validation approach. In the training cohort (N = 573 CLL), 92.5% showed productive IG light chain genes rearrangements, with IGKV4-1 (20.5%) and IGLV3-21 (19.0%) being the most common. A 99.0% somatic hypermutation cut-off was identified as the best predictor for time to first treatment (TTFT) in 414 Binet A CLL patients of the training cohort. Patients with unmutated (UM) light chain genes displayed a 10-year treatment free probability of 32.4% versus 73.2% for those with mutated (M) genes (p < 0.0001). Importantly, UM light chain genes maintained an independent association with a shorter TTFT when adjusted for the IPS-E prognostic model variables, that also includes IGHV mutational status. The validation cohort of 343 Rai 0 patients confirmed these findings, with UM light chain genes predicting a 7-year treatment free probability of 42.0% versus 73.7% for M genes (p < 0.0001). These results indicate that the mutational status of the light chain genes is an independent predictor of shorter TTFT in early-stage CLL patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellImmunoglobulin Light ChainsMutationImmunoglobulin Variable RegionImmunoglobulin Heavy ChainsHumansPrognosisMaleFemaleAgedMiddle AgedAged, 80 and overAdultBiomarkers, Tumor

Substanzen

Immunoglobulin Light ChainsImmunoglobulin Variable RegionImmunoglobulin Heavy ChainsBiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.
  • Division of Haematology, Ferrarotto Hospital, Catania, Italy.
  • Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi" DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, Italy.
  • Hematology Unit AO of Cosenza, Cosenza, Italy.
  • Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
  • Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.

ORCID-Profile: Jana Nabki, Bashar Al Deeban, Chiara Cosentino, Mohammad Almasri, Samir Mouhssine, Francesca Maiellaro, Luca Cividini, Riccardo Bomben, Valter Gattei, Gianluca Gaidano, Riccardo Moia

Zitieren

APA

Nabki, J., Al Deeban, B., Sium, A. M., Cosentino, C., Almasri, M., Awikeh, B., Maher, N., Bellia, M., Dondolin, R., Mouhssine, S., Talotta, D., Secomandi, E., Kogila, S., Ghanej, J., Maiellaro, F., Cividini, L., Rasi, S., Chiarenza, A., Olivieri, J., …, & Moia, R. (2025). Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement. Leukemia. https://doi.org/10.1038/s41375-024-02499-x

Vancouver

Nabki J, Al Deeban B, Sium AM, Cosentino C, Almasri M, Awikeh B, et al. Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement. Leukemia. 2025. doi:10.1038/s41375-024-02499-x

BibTeX
@article{Nabki2025,
  author = {Nabki, Jana and Al Deeban, Bashar and Sium, Abel Mehari and Cosentino, Chiara and Almasri, Mohammad and Awikeh, Bassel and Maher, Nawar and Bellia, Matteo and Dondolin, Riccardo and Mouhssine, Samir and Talotta, Donatella and Secomandi, Eleonora and Kogila, Sreekar and Ghanej, Joseph and Maiellaro, Francesca and Cividini, Luca and Rasi, Silvia and Chiarenza, Annalisa and Olivieri, Jacopo and Gentile, Massimo and Zaja, Francesco and Del Principe, Maria Ilaria and Laurenti, Luca and Bomben, Riccardo and Vit, Filippo and Bittolo, Tamara and Zucchetto, Antonella and Gattei, Valter and Gaidano, Gianluca and Moia, Riccardo},
  title = {Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement},
  journal = {Leukemia},
  year = {2025},
  doi = {10.1038/s41375-024-02499-x}
}
Kostenlos starten →